CellReady® for Alzheimer's Disease (A3D Trial)
Alzheimer's Disease
Phase 1Active
Key Facts
About Cell-Easy
Cell-Easy is a specialized CDMO focused on the complex manufacturing needs of cell-based therapies, including CAR-T, NK cells, MSCs, and iPSCs. The company leverages its deep biological and pharmaceutical expertise to offer technology-agnostic process development and GMP production services, aiming to shorten client timelines to clinical trials. Recent news highlights its expansion of GMP facilities and involvement in clinical trials for its proprietary CellReady® allogeneic MSC platform, indicating a hybrid service-plus-product strategy. Positioned in the high-growth ATMP sector, Cell-Easy partners with developers to navigate regulatory and scale-up challenges.
View full company profileOther Alzheimer's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| ALZN002 | Alzamend Neuro | Preclinical |
| P021 | Phanes Biotech | Preclinical |
| PB43D | Phanes Biotech | Preclinical |
| UB-311 | Vaxxinity | Phase 2 |
| Lecanemab | BioArctic | Launched |
| BAN2401 | BioArctic | Preclinical |
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| MK-6240 (florquinitau) | Lantheus Medical Imaging | Regulatory Filing |
| NAV-4694 (flutafuranol) | Lantheus Medical Imaging | Phase 3 |
| LNTH-2620/PI-2620 | Lantheus Medical Imaging | Phase 3 |
| itMSCs | Stemedica Cell Technologies | Clinical Development |